Stem Cell Therapy Market (COVID-19 Analysis) 2020-2025 Is Booming Worldwide with Comprehensive Study Explores Huge Revenue Scope in Future – Farming…

Global Stem Cell Therapy Market 2020-2025 Introduction and Scope:

The report on the Stem Cell Therapy Market aims to provide report readers with a diverse understanding of the different marketing opportunities prevalent in regional hubs. A thorough evaluation and evaluation of these factors can influence the prospects for gradual growth of the Stem Cell Therapy Market. The market research report provides an in-depth study of the market based on key segments such as product type, application, key companies and key regions, end users, and more. Research reports help participants understand their competitive strengths. It provides global information on the market, providing individual, weakness and competitive analysis for each participant. The report also covers the growth aspects of the market along with the challenges. The research report on the global Stem Cell Therapy Market provides information on the best manufacturers currently operating in this industry and a good market by market region.

The competitive landscape of the global Stem Cell Therapy Market is meticulously measured to identify key players in the arena by category and encourage novice market participants to step into the rapid market competition.

Request for a sample copy of this research report @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=re

The research report provides an assessment of the growth and other characteristics of the global Stem Cell Therapy Market by key regions and countries. The main regions with good markets in this industry are North America, Latin America, Europe, Asia Pacific and Middle East Africa. It also includes several strategies for estimating and determining market growth. It is also estimated that the global Stem Cell Therapy Market will determine the growth of certain segments of the industry. Additionally, this research report provides an analysis of the key drivers or drivers responsible for the growth of the Stem Cell Therapy Market. Additionally, the report provides some key reasons that could hinder the growth of the market during the forecast period. Therefore, this study provides an estimate of the growth of the market based on various segmentations and calculations by historical and current data.

Complete Summary with TOC Available @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=re

The information reflected in the Stem Cell Therapy Market Report comes from a variety of sources of information supported by primary and secondary research practices. This information comes from a variety of websites, journals and corporate websites that have been optimally validated by competent research analysts to ensure maximum adoption by market participants.

DROT Analysis: Global Stem Cell Therapy Market 1. Drivers: This report scouts various lucrative factors driving growth. 2. Barrier Analysis: A close review of threat potential and effective challenge management to ensure continued growth in the global Stem Cell Therapy Market 3. Opportunity Mapping: In this section of the report, readers can get a detailed reference to identify untapped market opportunities that could accelerate growth. The Stem Cell Therapy Market report is thoroughly structured to include the development of important milestones in the competitive spectrum, while enhancing competition while highlighting advanced market players with a thorough guide to core competencies and investment skills. The research elements presented in this advanced report have been prepared to ensure smooth decision making based on thorough and unbiased research practices.

Stem Cell Therapy Market Segmentation Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

Major Topics Covered in this Report: 1. Study Coverage 2. Executive Summary 3. Stem Cell Therapy Market Size by Manufacturers 4. Production by Regions 5. Consumption by Regions 6. Stem Cell Therapy Market Size by Type 7. Stem Cell Therapy Market Size by Application 8. Manufacturers Profiles 9. Production Forecasts 10. Consumption Forecast 11. Upstream, Industry Chain and Downstream Customers Analysis 12. Opportunities and Challenges, Threat and Affecting Factors 13. Key Findings 14. Appendix

Make An Enquiry About This Report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=re

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A Phone No.: USA: +1 972-362 -8199 / +91 9665341414

Read the original here:
Stem Cell Therapy Market (COVID-19 Analysis) 2020-2025 Is Booming Worldwide with Comprehensive Study Explores Huge Revenue Scope in Future - Farming...

Humanigen Secures US Patent for Lenzilumab in Preventing Cytokine Storm and Neurotoxicity Related to CAR-T Cell Therapy – BioSpace

Dec. 28, 2020 12:00 UTC

BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc.. (NASDAQ: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced the United States Patent and Trademark Office has issued a patent to the Company for the use of lenzilumab in prevention or treatment of cytokine storm and neurotoxicity in patients undergoing chimeric antigen receptor T (CAR-T) cell therapy.

The patent covers the use of lenzilumab to prevent or treat cytokine release syndrome (CRS), neurotoxicity and otherwise inhibit or reduce incidence or severity of CAR-T-related toxicities in patients undergoing CAR-T cell therapy. Lenzilumab binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), which has been identified as a key initiator of the inflammatory cascade triggering CAR-T cell therapy-related toxicities, such as CRS and neurotoxicity, which have been associated with prolonged hospitalization and intensive care unit stay.1,2

We believe lenzilumab can potentially play an important role in enhancing CAR-T cell therapy, and we are committed to advancing the development of lenzilumab to address cytokine storm associated with CAR-T cell therapy and other areas, said Cameron Durrant, MD, MBA, Chief Executive Officer, Humanigen. This patent underscores Humanigens pioneering approach to neutralizing GM-CSF with lenzilumab and the value of our robust pipeline across the many disease areas where cytokine storm plays a critical role, including COVID-19 and acute graft-versus-host disease.

The patent, titled Methods of Treating Immunotherapy-Related Toxicity Using a GM-CSF Antagonist, was issued on December 22, 2020 as U.S. Patent No. 10,870,703.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The companys immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit http://www.humanigen.com.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding the use of lenzilumab to treat CAR-T cell therapy-related toxicity, and statements regarding our beliefs relating to any of the other technologies in our current pipeline. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

1 Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133(7):697-709. doi:10.1182/blood-2018-10-881722 2 Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit Care Med. 2017;45(2):e124-e131. doi:10.1097/CCM.0000000000002053

View source version on businesswire.com: https://www.businesswire.com/news/home/20201228005075/en/

The rest is here:
Humanigen Secures US Patent for Lenzilumab in Preventing Cytokine Storm and Neurotoxicity Related to CAR-T Cell Therapy - BioSpace

Immunotherapy Continues on Positive Trajectory in Lymphoid Malignancies – OncLive

The treatment landscape of lymphoid malignancies space is rich with available immunotherapy agents, said Joshua Brody, MD. However, the field continues to push toward improving response rates by refining established modalities, such as CAR T-cell therapy and checkpoint inhibitors, as well as introducing novel modalities.

During the5th AnnualInternational Congress on Immunotherapies in Cancer, a program run by Physicians Education Resource (PER), Brody, an assistant professor of medicine, hematology, and medical oncology and director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, gave a presentation on established and upcoming immunotherapies in the lymphoid malignancy pipeline.

We are somewhat lucky, and maybe a bit spoiled in lymphoid malignancies, such as lymphomas and some B-cell malignancies, to have [seen] a huge amount of progress [with immunotherapy], said Brody.

However, lymphoid malignancies are highly heterogeneous. As such, not all patients are able to derive responses from the same therapy, Brody explained.

CAR T-cell therapy represents a significant advance in the treatment paradigms of several hematologic malignancies, including lymphoid malignancies, said Brody.

The results [of CAR T-cell therapy treatment] for patients with aggressive B-cell lymphomas have been amazing, Brody said. [CAR T-cell therapy] has shown higher response rates [in this space] than any other immunotherapy for any type of cancer; response rates are above 80%. Many of those [responses] are long lasting, complete remissions [CRs].

Notably, it is thought that patients who remain in CR for at least 6 to 12 months after CAR T-cell therapy infusion are likely cured of their lymphoma, Brody said. For example, it is likely that around 35% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) who receive CAR T-cell therapy are effectively cured.

Third-line [DLBCL], the most common type of lymphoma, [was thought to be] an incurable disease setting, said Brody. We [thought we could] cure people in the first- or second-line setting, but not beyond. Im not sure how we define a miracle, but it seems miraculous to me to change the incurable to partly curable.

Now, ongoing research efforts are attempting to refine CAR T-cell therapies to enhance responses and expand the utility of the modality to other hematologic malignancies beyond DLBCL, acute leukemia, and mantle cell lymphoma, explained Brody. For example, developing armored CAR T cells and fourth-generation CAR T cellsT cellsredirected for antigenunrestricted cytokineinitiated killingmay allow for improved delivery of cytotoxic payloads to liquid as well as solid tumors.

Additionally, novel CAR T-cell therapies may overcome some of the ongoing challenges observed with current, autologous products, such as toxicity, accessibility, and feasibility. For example, utilizing an allogeneic approach to CAR T-cell therapy may allow for an off-the-shelf option that could alleviate the risk of cytokine release syndrome and neurotoxicity.

Beyond CAR T-cell therapy, bispecific monoclonal antibodies, such as the investigational CD20/CD3-directed REGN1979 agent, could potentially be used in patients who progress after CAR T-cell therapy. Findings from a phase 1 trial (NCT02290951) demonstrated high objective response rates and CR rates among patients with heavily pretreated, relapsed/refractory NHL who were treated with REGN1979.1

Although the toxicity challenges of CAR T-cell therapies are likely not going to be solved with bispecific antibodies, the novel agents may offer an alternative option that can decrease the risk of adverse effects.

At least with [bispecific antibodies], we can tweak and optimize [dosing] a bit, explained Brody. CAR T-cell therapy is usually a one-shot therapy, [whereas] bispecifics can be given in low, medium, or high doses. We can up-titrate the therapy to try to minimize or avoid some of these toxicities.

Additionally, bispecific antibodies are potentially able to avoid antigen escape, which is a common concern with CD19/CD20-directed CAR T-cell therapies, Brody explained.

PD-1/PD-L1 inhibitors have transformed the treatment landscape in melanoma, lung cancer, renal cell carcinoma, and bladder cancer. However, Hodgkin lymphoma is the most responsive disease to antiPD-1 agents because chromosomal amplifications or translocations are hardwired to overexpress PD-1, Brody said.

As such, responses with checkpoint inhibitors, such as nivolumab (Opdivo), are seen in around 70% of patients with Hodgkin lymphoma who progress following autologous stem cell transplant.2

The introduction of checkpoint inhibitors to this space has been particularly encouraging for younger patients who fail curative-intent chemotherapy and who, historically, had dismal prognoses.

Currently, ongoing efforts are attempting to bring PD-1 inhibitors to the second-line setting and, potentially, up-front settings in combination with chemotherapy.

Although it is true that hot tumors are more likely to respond to immunotherapy compared with cold tumors, it is not the only factor that contributes to whether a tumor will respond. As such, alternative methods of improving immune response in patients with lymphoid malignancies are being evaluated.

For example, one investigational method is to utilize radiotherapy or other means to mobilize dendritic cells loaded with tumor antigens to antigen-presenting cells. Ultimately, this compound could serve as a therapeutic anti-cancer vaccine to deliver the antigens, as well as costimulatory signals, to the cancer cells.

As such, an ongoing trial (NCT03789097) led by Brody is currently testing an in situ vaccine combining radiation therapy, the immune cell growth factor Flt3L/CDX-301, the immune-cell activating factor Poly-ICLC, and pembrolizumab (Keytruda).3 Initial findings from the study have yielded encouraging results, according to Brody.

In situ vaccines such as this may be able to cross prime T cells and increase the effectiveness of immunotherapy for patients, Brody concluded.

See the original post:
Immunotherapy Continues on Positive Trajectory in Lymphoid Malignancies - OncLive

Stem Cell Therapy Market Size 2020 | Opportunities, Regional Overview, Top Leaders, Revenue and Forecast to 2025 – LionLowdown

Global Stem Cell Therapy Market 2020-2025 Introduction and Scope:

The Global Stem Cell Therapy Market is a competitive source of real-time data and information related to important facts and figures related to market analysis, competitive spectrum, regional scope and opportunity assessment, and understanding barriers that are important growth catalysts. The details of the COVID-19 impact and possible damage recovery plan have been discussed at length to guide important business decisions. The report is ready to refer to documents that share important details of the market from a historical perspective, so readers can measure concurrent developments to make accurate growth speculations and make predictive assessments. The report provides an exclusive overview of the competitive spectrum to identify key giants and ambitious players seeking to easily drive market penetration in the global Stem Cell Therapy Market ecosystem.

This report on the global Stem Cell Therapy Market provides an easily accessible roadmap to assess the league of factors and influencers such as untapped market opportunities and trends pioneering a growth timeline favorable for this market.

Request for a sample copy of this research report @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=re

This consciously designed market research protocol inspires our research experts and predictors to devote more effort to discovering thorough information so that critical research colleagues and knowledge collectors can optimally find multidimensional information for the best market predictions. Do it. This Advanced Strategy-Based Stem Cell Therapy Market Report presentation is based on market size and dynamics, dominant and popular trends, market shares, investment plans, pricing strategies, and drivers driving overall steady and long-term growth in the global Stem Cell Therapy Market.

The Stem Cell Therapy Market report contains details related to various supplier activities, trend analysis, DROT assessment, and potential business decisions to ensure a successful position despite ongoing competition. In addition, in the report, readers will receive important company profiles, product development, pricing, production and details related to the development of raw materials and equipment that make up important report content.

The Stem Cell Therapy Market report also entails specific details on the analysis of COVID-19, skillfully highlighting potential details of the pandemic impact across the current state, in addition to hovering over future developments. The COVID-19 outbreak has had a myriad of impacts on businesses and their normal growth process, and this research report is designed to adequately encourage an efficient and fast recovery process.

Complete Summary with TOC Available @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=re

Key questions answered in the report: What are the key developments influencing the global Stem Cell Therapy Market and its growth? What is the impact of global Stem Cell Therapy Market development on industry and market participants in the near and far future? What types of global Stem Cell Therapy Market are evolving? What are the evolving applications of the global Stem Cell Therapy Market? What are the key characteristics that will influence the global Stem Cell Therapy Market growth during the study period? Who are the major global players operating in the market? How are the major players using the existing global Stem Cell Therapy Market situation?

Stem Cell Therapy Market Segmentation Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCs Bone Marrow-Derived Mesenchymal SCs Embryonic SCs Other Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal Disorders Wounds & Injuries Cardiovascular Diseases Gastrointestinal Diseases Immune System Diseases Other Applications

Major Topics Covered in this Report: 1. Study Coverage 2. Executive Summary 3. Stem Cell Therapy Market Size by Manufacturers 4. Production by Regions 5. Consumption by Regions 6. Stem Cell Therapy Market Size by Type 7. Stem Cell Therapy Market Size by Application 8. Manufacturers Profiles 9. Production Forecasts 10. Consumption Forecast 11. Upstream, Industry Chain and Downstream Customers Analysis 12. Opportunities and Challenges, Threat and Affecting Factors 13. Key Findings 14. Appendix

Make An Enquiry About This Report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=re

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A Phone No.: USA: +1 972-362 -8199 / +91 9665341414

Read the original:
Stem Cell Therapy Market Size 2020 | Opportunities, Regional Overview, Top Leaders, Revenue and Forecast to 2025 - LionLowdown

Adipose Derived Stem Cell Therapy Market 2020 Analysis, Growth, Size, Shares, Drivers, Advancements, Challenges, Sophisticated Demand & Key…

CMI presents an in-depth overview of the Global Adipose Derived Stem Cell Therapy Market Study, detailing the latest product/industry coverage and market forecasts and status by 2027. Market research is categorized as a key area to accelerate marketization. The current market is evolving its presence and some of the major players in the study are

This study focuses on the Global Adipose Derived Stem Cell Therapy Market status, future forecast, growth opportunity, key market, and emerging players. The study objectives are to present the Adipose Derived Stem Cell Therapy growth in Key regions. In order to provide valuable insight into each key element of the market, the highest and slowest growing market segment in the study is described. Newmarket participants are emerging and are accelerating the transition in the antistatic market. Merger and acquisition activities are expected to change the market environment for this industry.

Adipose derived stem cells (ADSCs) are stem cells derived from adipocytes, and can differentiate into variety of cell types. ADSCs have multipotency similar to bone marrow mesenchymal stem cells, thus ADSCs substitute for bone marrow as a source of stem cells. Numerous manual and automatic stem cell separation procedures are adopted in order to separate adipose stem cells (ASCs) from adipose tissue. Flow cytometry can also be used to isolate ADSCs from other stem cells within a cell solution.

Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2357

The Global Adipose Derived Stem Cell Therapy is segmented by:

By Product Type: Global Adipose Derived Stem Cell Therapy Market, By Application.

Regional Markets: United States, Europe, China, Japan, Southeast Asia, India & Central & South America

List of Companies Mentioned:

1) Does Study provide Latest Impact on the Market due to COVID & Slowdown?

Yes, the study has considered a chapter on Impact Analysis and this 2020 Edition of the report provides detailed analysis and its impact on growth trends and market sizing to better understand the current scenario.

2) How companies are selected or profiled in the report?

The list of some players that are profiled in the report includes .. the list is sorted to come up with a sample size of at least 50 to 100 companies having greater topline value to get their segment revenue for market estimation.

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Is it possible to narrow down business segments by Application of this study?

Yes, depending upon the data availability and feasibility check by our Research Analyst, a further breakdown in business segments by end-use application in relation to type can be provided (If applicable) by Revenue Size or Volume*.

4) What is the base year of the study? What time frame is covered in the report?

Furthermore, the years considered for the study are as follows:

Historical year 2014-2019

Base year 2019

Forecast period** 2020 to 2027 [** unless otherwise stated]

** We will also include opportunities to utilize in micro markets that stakeholders can invest in, a detailed analysis of key competitors, and key services. **

Global Adipose Derived Stem Cell Therapy Market What to expect from this report:

Focused Study on Niche Strategy and Market Development & penetration Scenario

Top 10 Global Adipose Derived Stem Cell Therapy Companies in Global Market Share Analysis: Leaders and Laggards in 2017, 2019

Gain strategic insights on competitor information to formulate effective R&D moves

Identify emerging players and create effective counter-strategies to outpace competitive edge

Identify important and diverse product types/services offering carried by major players for market development

And many more .

LIMITED TIME OFFER Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Apply Promo Code CHRISTMAS2020 And Get Instant Discount Of USD 1000

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/2357

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: Global Adipose Derived Stem Cell Therapy MarketLandscape

PART 06: Global Adipose Derived Stem Cell TherapyMarket Sizing

PART 07: Global Adipose Derived Stem Cell TherapyMarket Segmentation

PART 08: CUSTOMER LANDSCAPE

PART 10: DECISION FRAMEWORK

PART 09: REGIONAL LANDSCAPE

PART 11: MARKET DYNAMICS: DRIVERS, TRENDS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

Read the original:
Adipose Derived Stem Cell Therapy Market 2020 Analysis, Growth, Size, Shares, Drivers, Advancements, Challenges, Sophisticated Demand & Key...

Stem cells from cord blood can now be used across many conditions: Mayur Abhaya, MD & CEO, LifeCell Internat.. – ETHealthworld.com

Shahid Akhter, editor, ETHealthworld, spoke to Mayur Abhaya, MD & CEO, LifeCell International, to know more about the latest advancements in Stem cell industry and how it has recovered from the Covid challenges. Impact and challenges of Covid-19 on the Stem cell industry ? One of the biggest issues faced by the stem cell industry during the pandemic was the transport of the cells after collection at birth. It needs to reach the lab within 72 hours and in the case of bone marrow stem cell from donation all the way until it reaches the patient that also has to be completed within 72 hours. The bone marrow cells cannot be handed over in courier. It has to be manually hand carried and that created a huge logistics hurdle were transplants significantly reduced in numbers because of the availability of donors and the transport issues around it.

What are the current global trends in the Stem Cell Industry at large? The recent clinical progress that has been made in the medical space of stem cell transplantation is that now cord blood is considered as a better source than bone marrow cells. This was found in a research study based in US, published in 2020. They have also shown that stem cells from the cord blood can now be used across many conditions with the same treatment protocol. Besides that, the preparation of the patient is different in different conditions but now they have simplified that and reduced the risk of death to a very, very low number. So the cord blood is preferred, as the outcomes are improving.

Another major milestone during this pandemic that we were able to help was to support a transplant were a child having Aplastic Anaemia needed not one but two cord blood units for the transplant and within the family they couldnt find a match. Luckily because of the LifeCell network and the inventory size of 50,000 units we were able to meet the requirements of the transplant and happy to share the outcome was very successful. So LifeCell ensures that we have appropriate training for its paramedical staff and they are also provided with the appropriate personal protective gears. There are restrictions on the entry of the team inside during the collection we work with the medical staff in the collection rooms, in the operation theatres to ensure a smooth and a well organised collection and even at the lab we have protocols that ensures hygiene and safety within the team and, the operating rooms we have for processing are also well managed.

Your future plans to ensure the smooth collection of Cord Blood? To ensure business continuity we have our teams located very close to our lab itself, you know, so about 100+ member team are placed within a Kilometer of the operating facility. We have adequate stocks, lots of the testing and the processing, consumables that we use are imported. We, at least, maintain 3 month inventory. We also have onsite power back up systems which include a month of diesel supply, month of liquid nitrogen supply and the teams also have a plan that we have a back site also with arrangements done. If for any reason we have cut off of the Chennai centre we have arrangements with an alternate lab to ensure the continuity of the operations

See the rest here:
Stem cells from cord blood can now be used across many conditions: Mayur Abhaya, MD & CEO, LifeCell Internat.. - ETHealthworld.com

Comprehensive Report on NK Cell Therapy and Stem Cell Therapy Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | Chipscreen…

NK Cell Therapy and Stem Cell Therapy Marketresearch report is the new statistical data source added byA2Z Market Research.

NK Cell Therapy and Stem Cell Therapy Market is growing at a High CAGR during the forecast period 2021-2027. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

NK Cell Therapy and Stem Cell Therapy Marketresearch is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=325609

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Chipscreen Biosciences, Innate Pharma SA, Osiris Therapeutics, Chiesi Pharmaceuticals, Molmed, JCR Pharmaceutical, Altor BioScience Corporation, Affimed NV, Takeda Pharmaceutical, Pharmicell, Medi-post, NuVasive, Anterogen.

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global NK Cell Therapy and Stem Cell Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the NK Cell Therapy and Stem Cell Therapy markets trajectory between forecast periods.

Global NK Cell Therapy and Stem Cell Therapy Market Segmentation:

Market Segmentation: By Type

NK Cell Therapy Stem Cell Therapy

Market Segmentation: By Application

Hospital & clinics Regenerative medicine centers Diagnostic centers Research institutes Others

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=325609

Regions Covered in the Global NK Cell Therapy and Stem Cell Therapy Market Report 2021: The Middle East and Africa(GCC Countries and Egypt) North America(the United States, Mexico, and Canada) South America(Brazil etc.) Europe(Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The cost analysis of the Global NK Cell Therapy and Stem Cell Therapy Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the NK Cell Therapy and Stem Cell Therapy market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the NK Cell Therapy and Stem Cell Therapy market.

Table of Contents

Global NK Cell Therapy and Stem Cell Therapy Market Research Report 2021 2027

Chapter 1 NK Cell Therapy and Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global NK Cell Therapy and Stem Cell Therapy Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=325609

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Continue reading here:
Comprehensive Report on NK Cell Therapy and Stem Cell Therapy Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | Chipscreen...

The Top 5 Most-Read Oncology Stories of 2020 – AJMC.com Managed Markets Network

Our 5 most-read oncology stories and most-watched videos this year highlighted cancer care policy, diversity, and the growing practice of remote cancer care.

Our 5 most-read oncology stories and most-watched videos this year highlighted cancer care policy, diversity, and the growing practice of remote cancer care. It was a dynamic year from a policy perspective, with delays and accommodations from CMS amid a global pandemic. Here are the top stories in oncology this year.

5. Dr Kerin Adelson on Changes in Care Coordination Precipitated by OCM

The Oncology Care Model (OCM) has impacted the way oncologists practice, said Kerin Adelson, MD, associate professor, chief quality officer, and deputy chief medical officer for Smilow Cancer Hospital at Yale New Haven/Yale Cancer Center. With the model focused on reducing unnecessary utilization, Adelson said that the resources it provides have enhanced care coordination and led to the formation of novel infrastructure and clinical pathways.

Watch the video.

4. Dr Karen Winkfield Discusses Importance of Workforce Diversity in Oncology

Disparities in health care have been highlighted more than ever this year, with the pandemic bringing to light and exacerbating longstanding racial and economic divides in those who receive the care they need. Karen Winkfield, MD, PhD, incoming executive director of the Meharry-Vanderbilt Alliance, spotlighted the need for minority representation in the radiation oncology workforce.

Watch the video.

3. How Federal Policy Decisions Are Influencing Cancer Care

The cost of cancer is driven up by novel therapies, with unprecedented progress fostering cancers evolvement into a chronic disease. But federal policy decisions are influencing oncologists ability to provide the best possible therapies to every patient. Debra Patt, MD, PhD, MBA, MPH, of Texas Oncology, addressed the predicament at The American Journal of Managed Cares 2020 Patient-Centered Oncology Care meeting.

Read the full article.

2. Dr Sara Douglas: Distance Caregivers of Patients With Cancer Have Distinct Needs

The high degree of uncertainty associated with providing remote care means that distance caregivers of patients with cancer have unique needs for information and require customized education, explained Sara L. Douglas, PhD, RN, the Gertrude Perkins Oliva Professor in Oncology Nursing and associate dean for research at the Frances Payne Bolton School of Nursing at Case Western Reserve University in Cleveland, Ohio.

Watch the video.

1. Tafasitamab Combination Approved for Adults With R/R DLBCL

Tafasitamab-cxix was approved by the FDA on July 31 this year for use in combination with lenalidomide for second-line treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and the news took the top spot in our list of most-read oncology stories this year. The approval, which was based on phase 2 results for 80 patients in the L-MIND trial, meets the needs of patients not eligible for an autologous stem cell transplant.

Read the full article.

Read more from the original source:
The Top 5 Most-Read Oncology Stories of 2020 - AJMC.com Managed Markets Network

Adipose Tissue-derived Stem Cell Therapy Market Share Analysis, Application, Strategies of Key Players & Forecast to 2025 – Factory Gate

The Global Adipose Tissue-derived Stem Cell Therapy Market report offers users the detailed study of the market and its main aspects. The study on Global Adipose Tissue-derived Stem Cell Therapy Market, offers profound understandings about the Adipose Tissue-derived Stem Cell Therapy Market covering all the essential aspects of the market. The report provides competitive pipeline landscape of the Global Factors like production, market share, revenue rate, regions and key players define a market study start to end. This report gives an overview of market valued in the year 2019 and its growth in the coming years till 2025.

This study covers following key players: The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3. AlloCure Tissue Genesis Antria Cellleris Corestem Celgene Corporation Mesoblast Cytori Therapeutics Pluristem Therapeutics Intrexon Lonza BioRestorative Therapies Pluristem Therapeutics iXCells Biotechnologies Cyagen Celltex Therapeutics Corporation

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4721400?utm_source=Yogi

The study is done with the help of analysis such as SWOT analysis and PESTEL analysis. It consists of the detailed study of current market trends along with the past statistics. The past years are considered as reference to get the predicted data for the forecast period. The report covers complete analysis of the Adipose Tissue-derived Stem Cell Therapy Market on the basis of regional and Global level. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry.

There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. There is a target set in market that every marketing strategy has to reach. In addition, it also covers political and social factors which is likely to affect the growth of the market. It also covers and analysis several segments which are present in the market. A significant development has been recorded by the market of Adipose Tissue-derived Stem Cell Therapy, in past few years. It is also for it to grow further. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry.

Access Complete Report @ https://www.orbisresearch.com/reports/index/global-adipose-tissue-derived-stem-cell-therapy-market-growth-status-and-outlook-2020-2025?utm_source=Yogi

Market segment by Type, the product can be split into Segmentation by type: breakdown data from 2015 to 2020 in Section 2.3; and forecast to 2025 in section 10.7. Autologous Stem Cells Allogeneic Stem Cells

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8. Therapeutic Application Research Application

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8. Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3. AlloCure Tissue Genesis Antria Cellleris Corestem Celgene Corporation Mesoblast Cytori Therapeutics Pluristem Therapeutics Intrexon Lonza BioRestorative Therapies Pluristem Therapeutics iXCells Biotechnologies Cyagen Celltex Therapeutics Corporation

Market segment by Application, split into Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8. Therapeutic Application Research Application

One of the ways for the estimation for the growth of the market is estimation of the market share by the regions which is likely to contribute to the growth of the market in the estimated forecast period. In this, the growth and fall of each region is covered which is likely to boost the growth of the Adipose Tissue-derived Stem Cell Therapy Market. In addition, to determine and use precise methods, research methodology such as the qualitative and quantitative data is used for the estimation and determination of the Global Adipose Tissue-derived Stem Cell Therapy Market.

For Enquiry before buying report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4721400?utm_source=Yogi

About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us: Hector Costello Senior Manager Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas 75204, U.S.A. Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Here is the original post:
Adipose Tissue-derived Stem Cell Therapy Market Share Analysis, Application, Strategies of Key Players & Forecast to 2025 - Factory Gate

Study clarifies the impact of getting old on hematopoietic stem cells – Microbioz India

By shifting mouse elderly hematopoietic stem cells (aged HSCs) to the environment of young mice (bone marrow niche), it was shown that the pattern of stem cell gene expression was rejuvenated to that of young hematopoietic stem cells. On the other hand, the function of elderly HSCs failed to recover in the young bone marrow niche. The epigenome (DNA methylation) of aged HSCs didnt change significantly even in the young bone marrow niche, and DNA methylation profiles were found to be a better index than the gene expression pattern of aged HSCs.

A research group headed by Professor Atsushi Iwama in the Division of Stem Cell and Molecular Medicine, The Institute of Medical Science, The University of Tokyo (IMSUT) declared these world-first Outcomes and was published in the Journal of Experimental Medicine (online) on November 24th.

The results will contribute to the development of treatments for age-related blood diseases.

Professor Atsushi Iwama, Lead Scientist, IMSUT

The research group investigated whether rejuvenating aged HSCs in a young bone marrow market environment would rejuvenate.

Tens of thousands of elderly hematopoietic stem/progenitor cells gathered from 20-month-old mice were transplanted into 8-week-old young mice without pretreatment like irradiation. After two months of follow-up, they collected bone marrow cells and performed flow cytometric analysis.

The research team also transplanted 10-week-old young mouse HSCs for comparison. In addition, engrafted aged HSCs were fractionated and RNA sequence analysis and DNA methylation analysis were conducted.

They discovered that engrafted elderly HSCs were less capable of producing hematopoietic cells compared to younger HSCs. They also showed that differentiation of aged HSCs into multipotent progenitor cells was persistently impaired even in the young bone marrow market, and that the direction of differentiation was biased. It was found that the transfer of aged HSCs into the young bone marrow market does not enhance their stem cell function.

A more detailed analysis may reveal mechanisms that irreversibly affect aged HSC function Aging studies focusing on HSCs have been chased in mice with a bone marrow transfer model. However, the effect of aging on HSCs remains to be clarified.

Professor Iwama says as follows. This analysis has a substantial impact because it clarified the effect of aging on HSCs. Our results are expected to contribute to further elucidation of the mechanism of aging in HSCs and comprehension of the pathogenic mechanism of age-related blood disorders.

Source:

Journal reference:

Kuribayashi, W.,et al.(2020) Limited rejuvenation of aged hematopoietic stem cells in young bone marrow niche.Journal of Experimental Medicine.doi.org/10.1084/jem.20192283.

See more here:
Study clarifies the impact of getting old on hematopoietic stem cells - Microbioz India